Skip to main content
Top
Published in: Digestive Diseases and Sciences 6/2023

Open Access 11-02-2023 | Joint Pain | Original Article

Ulcerative Colitis-Symptom Questionnaire: Valid for Use in Adults with Moderately to Severely Active Ulcerative Colitis

Authors: Julian Panes, Anthony Otley, Yuri Sanchez Gonzalez, Kristina Fitzgerald, Wen Zhou, Dapo Ilo, Triza Brion, Muna J. Tahir

Published in: Digestive Diseases and Sciences | Issue 6/2023

Login to get access

Abstract

Background

Due to wide-ranging impacts of Ulcerative Colitis (UC), regulatory authorities emphasize the importance of including validated patient-reported symptom severity measures in clinical trials.

Aim

To describe the development and validation of the Ulcerative Colitis-Symptom Questionnaire (UC-SQ).

Methods

The UC-SQ was developed in a qualitative study involving a targeted literature review, semi-structured concept elicitation interviews, and combined concept elicitation/cognitive interviews. Measurement properties, including item-level analyses, factor structure, reliability, validity, responsiveness, and clinically meaningful change were evaluated using data from a phase 2b, randomized trial in adults with UC (N = 113).

Results

Fourteen symptom concepts were elicited across 22 interviews, with saturation at the fifth interview. Twenty-two items were unmodified as cognitive interview participants interpreted underlying concepts correctly. Instructions were clear and items were relevant, with appropriate response options and recall periods. Reduction to 17 items was completed prior to psychometric testing. Two items (joint pain/constipation) did not contribute to reliability in initial testing and were included as non-scored items. The 15-item UC-SQ showed evidence of internal consistency (α = 0.86) and test–retest reliability (intraclass correlation coefficient = 0.88). The UC-SQ discriminated by disease severity as defined by Mayo and Inflammatory Bowel Disease Questionnaire scores (p < 0.0001). Convergent validity was supported by strong correlations with criterion measures. The UC-SQ was responsive in patients indicating change in other measures. A 10-point decrease from baseline indicated within-patient meaningful improvement.

Conclusions

The UC-SQ is reliable, valid and responsive, with a 10-point improvement estimating within-patient clinically meaningful improvement. The tool is fit-for-purpose as a key endpoint in pivotal UC trials.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ye Y, Manne S, Treem WR, Bennett D. Prevalence of inflammatory bowel disease in pediatric and adult populations: recent estimates from large national databases in the United States, 2007–2016. Inflamm Bowel Dis. 2020;26:619–625.PubMed Ye Y, Manne S, Treem WR, Bennett D. Prevalence of inflammatory bowel disease in pediatric and adult populations: recent estimates from large national databases in the United States, 2007–2016. Inflamm Bowel Dis. 2020;26:619–625.PubMed
2.
go back to reference Ng SC, Shi HY, Hamidi N et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769–2778.CrossRefPubMed Ng SC, Shi HY, Hamidi N et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769–2778.CrossRefPubMed
3.
go back to reference Gajendran M, Loganathan P, Jimenez G et al. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019;65:100851.CrossRefPubMed Gajendran M, Loganathan P, Jimenez G et al. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019;65:100851.CrossRefPubMed
4.
go back to reference Tripathi K, Feuerstein JD. New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance. Drugs Context. 2019;8:212572.CrossRefPubMedPubMedCentral Tripathi K, Feuerstein JD. New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance. Drugs Context. 2019;8:212572.CrossRefPubMedPubMedCentral
5.
go back to reference Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103–110.CrossRefPubMed Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103–110.CrossRefPubMed
6.
go back to reference US Food and Drug Administration. Ulcerative colitis: clinical trial endpoints guidance for industry. 2016. US Food and Drug Administration. Ulcerative colitis: clinical trial endpoints guidance for industry. 2016.
7.
go back to reference Reinisch W, Gottlieb K, Colombel JF et al. Comparison of the EMA and FDA guidelines on ulcerative colitis drug development. Clin Gastroenterol Hepatol. 2019;17:1673–1679.CrossRefPubMed Reinisch W, Gottlieb K, Colombel JF et al. Comparison of the EMA and FDA guidelines on ulcerative colitis drug development. Clin Gastroenterol Hepatol. 2019;17:1673–1679.CrossRefPubMed
8.
go back to reference US Food and Drug Administration. Principles for selecting, developing, modifying, and adapting patient-reported outcome instruments for use in medical device evaluation. 2020. US Food and Drug Administration. Principles for selecting, developing, modifying, and adapting patient-reported outcome instruments for use in medical device evaluation. 2020.
9.
go back to reference US Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. 2009. US Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. 2009.
10.
go back to reference European Medicines Agency. Guideline on the development of new medicinal products for the treatment of Ulcerative Colitis. In: (CHMP) CfMPfHU, ed. CHMP/EWP/18463/2006 Rev.1 ed 2018. European Medicines Agency. Guideline on the development of new medicinal products for the treatment of Ulcerative Colitis. In: (CHMP) CfMPfHU, ed. CHMP/EWP/18463/2006 Rev.1 ed 2018.
11.
go back to reference European Medicines Agency. Reflection paper on the regulatory guidance for the use of health related quality of life (HRQL) measures in the evaluation of medicinal products. 2005. European Medicines Agency. Reflection paper on the regulatory guidance for the use of health related quality of life (HRQL) measures in the evaluation of medicinal products. 2005.
12.
go back to reference Joffe H, Yardley L. Content and thematic analysis. In: Marks DF, Yardley L, eds. Research methods for clinical and health psychology, vol56. Thousand Oaks: SAGE Publications; 2004; 68. Joffe H, Yardley L. Content and thematic analysis. In: Marks DF, Yardley L, eds. Research methods for clinical and health psychology, vol56. Thousand Oaks: SAGE Publications; 2004; 68.
13.
go back to reference Kerr C, Nixon A, Wild D. Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes research. Expert Rev Pharmacoecon Outcomes Res. 2010;10:269–281.CrossRefPubMed Kerr C, Nixon A, Wild D. Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes research. Expert Rev Pharmacoecon Outcomes Res. 2010;10:269–281.CrossRefPubMed
14.
go back to reference Lim CR, Harris K, Dawson J, Beard DJ, Fitzpatrick R, Price AJ. Floor and ceiling effects in the OHS: an analysis of the NHS PROMs data set. BMJ Open. 2015;5:e007765.CrossRefPubMedPubMedCentral Lim CR, Harris K, Dawson J, Beard DJ, Fitzpatrick R, Price AJ. Floor and ceiling effects in the OHS: an analysis of the NHS PROMs data set. BMJ Open. 2015;5:e007765.CrossRefPubMedPubMedCentral
15.
go back to reference Nunnally JC. Psychometric theory, 2nd edn. New York: McGraw-Hill; 1978. Nunnally JC. Psychometric theory, 2nd edn. New York: McGraw-Hill; 1978.
16.
go back to reference Nunnally JC. Psychometric theory 3E. New York: Tata McGraw-Hill Education; 1994. Nunnally JC. Psychometric theory 3E. New York: Tata McGraw-Hill Education; 1994.
17.
go back to reference Stevens SS. Handbook of experimental psychology. New York: Wiley; 1951. Stevens SS. Handbook of experimental psychology. New York: Wiley; 1951.
18.
19.
go back to reference McGraw KO, Wong SP. Forming inferences about some intraclass correlation coefficients. Psychol Methods. 1996;1:30.CrossRef McGraw KO, Wong SP. Forming inferences about some intraclass correlation coefficients. Psychol Methods. 1996;1:30.CrossRef
20.
go back to reference Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86:420–428.CrossRefPubMed Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86:420–428.CrossRefPubMed
21.
go back to reference Chassany O, Sagnier P, Marquis P, Fullerton S, Aaronson N. Patient-reported outcomes: the example of health-related quality of life—a European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inf J. 2002;36:209–238.CrossRef Chassany O, Sagnier P, Marquis P, Fullerton S, Aaronson N. Patient-reported outcomes: the example of health-related quality of life—a European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inf J. 2002;36:209–238.CrossRef
22.
go back to reference Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale: Lawrence Erlbaum Associates, Publishers; 1988. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale: Lawrence Erlbaum Associates, Publishers; 1988.
23.
go back to reference da Silva BC, Lyra AC, Rocha R, Santana GO. Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis. World J Gastroenterol. 2014;20:9458–9467.CrossRefPubMedPubMedCentral da Silva BC, Lyra AC, Rocha R, Santana GO. Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis. World J Gastroenterol. 2014;20:9458–9467.CrossRefPubMedPubMedCentral
24.
go back to reference Joyce JC, Waljee AK, Khan T et al. Identification of symptom domains in ulcerative colitis that occur frequently during flares and are responsive to changes in disease activity. Health Qual Life Outcomes. 2008;6:69.CrossRefPubMedPubMedCentral Joyce JC, Waljee AK, Khan T et al. Identification of symptom domains in ulcerative colitis that occur frequently during flares and are responsive to changes in disease activity. Health Qual Life Outcomes. 2008;6:69.CrossRefPubMedPubMedCentral
25.
go back to reference Lynch WD, Hsu R. Ulcerative Colitis. In: StatPearls. Treasure Island: StatPearls Publishing; 2021. Lynch WD, Hsu R. Ulcerative Colitis. In: StatPearls. Treasure Island: StatPearls Publishing; 2021.
26.
go back to reference Maunder RG, Greenberg GR. Comparison of a disease activity index and patients’ self-reported symptom severity in ulcerative colitis. Inflamm Bowel Dis. 2004;10:632–636.CrossRefPubMed Maunder RG, Greenberg GR. Comparison of a disease activity index and patients’ self-reported symptom severity in ulcerative colitis. Inflamm Bowel Dis. 2004;10:632–636.CrossRefPubMed
27.
go back to reference Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756–1770.CrossRefPubMed Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756–1770.CrossRefPubMed
28.
go back to reference Waljee AK, Joyce JC, Wren PA, Khan TM, Higgins PD. Patient reported symptoms during an ulcerative colitis flare: a Qualitative Focus Group Study. Eur J Gastroenterol Hepatol. 2009;21:558–564.CrossRefPubMedPubMedCentral Waljee AK, Joyce JC, Wren PA, Khan TM, Higgins PD. Patient reported symptoms during an ulcerative colitis flare: a Qualitative Focus Group Study. Eur J Gastroenterol Hepatol. 2009;21:558–564.CrossRefPubMedPubMedCentral
29.
go back to reference Higgins PDR, Harding G, Revicki DA et al. Development and validation of the Ulcerative Colitis patient-reported outcomes signs and symptoms (UC-pro/SS) diary. J Patient Rep Outcomes. 2017;2:26.CrossRefPubMed Higgins PDR, Harding G, Revicki DA et al. Development and validation of the Ulcerative Colitis patient-reported outcomes signs and symptoms (UC-pro/SS) diary. J Patient Rep Outcomes. 2017;2:26.CrossRefPubMed
Metadata
Title
Ulcerative Colitis-Symptom Questionnaire: Valid for Use in Adults with Moderately to Severely Active Ulcerative Colitis
Authors
Julian Panes
Anthony Otley
Yuri Sanchez Gonzalez
Kristina Fitzgerald
Wen Zhou
Dapo Ilo
Triza Brion
Muna J. Tahir
Publication date
11-02-2023
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2023
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-022-07807-y

Other articles of this Issue 6/2023

Digestive Diseases and Sciences 6/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.